Vertex Pharmaceuticals (VRTX) Share-based Compensation (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Share-based Compensation of $166.4 million for Q1 2026, little changed year-over-year from $166.1 million in Q1 2025, and up 205.05% quarter-over-quarter from -$158.4 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Share-based Compensation (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $166.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation changed 0.18% year-over-year to $166.4 million; the TTM figure through Mar 2026 stood at $370.2 million (up 9.66% YoY), while the FY2025 annual figure was $369.9 million, down 8.67% from the prior year.
- Share-based Compensation for Q1 2026 stood at $166.4 million, up from -$158.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $233.5 million in Q1 2024, with the low at -$158.4 million in Q4 2025.
- The 5-year median for Share-based Compensation is $130.9 million (2023), against an average of $99.7 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 172.14% in 2022, then surged 9833.33% in 2023.
- Vertex Pharmaceuticals' Share-based Compensation stood at $2.1 million in 2022, then soared by 9833.33% to $208.6 million in 2023, then tumbled by 160.26% to -$125.7 million in 2024, then declined by 26.01% to -$158.4 million in 2025, then surged by 205.05% to $166.4 million in 2026.
- Business Quant data shows VRTX's Share-based Compensation at $166.4 million in Q1 2026, -$158.4 million in Q4 2025, and $194.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.10 Mn |
| Jun 30, 2026 | 108.10 Mn |
| Mar 31, 2026 | 166.40 Mn |
| Mar 31, 2026 | 166.40 Mn |
| Dec 31, 2025 | -158.40 Mn |
| Dec 31, 2025 | -158.40 Mn |
| Sep 30, 2025 | 194.90 Mn |
| Sep 30, 2025 | 194.90 Mn |
| Jun 30, 2025 | 167.30 Mn |
| Jun 30, 2025 | 167.30 Mn |
| Mar 31, 2025 | 166.10 Mn |
| Mar 31, 2025 | 166.10 Mn |
| Dec 31, 2024 | -125.70 Mn |
| Dec 31, 2024 | -125.70 Mn |
| Sep 30, 2024 | 184.60 Mn |
| Sep 30, 2024 | 184.60 Mn |
| Jun 30, 2024 | 112.60 Mn |
| Jun 30, 2024 | 112.60 Mn |
| Mar 31, 2024 | 233.50 Mn |
| Mar 31, 2024 | 233.50 Mn |